Abstract:Japan faces an increasing incidence of heart disease, owing to a shift towards a westernized lifestyle and an aging demographic. In cases where conventional interventions are not appropriate, regenerative medicine offers a promising therapeutic option. However, the use of stem cells has limitations, and therefore, "direct cardiac reprogramming" is emerging as an alternative treatment. Myocardial regeneration transdifferentiates cardiac fibroblasts into cardiomyocytes in situ.Three cardiogenic transcription factors: Gata4, Mef2c, and Tbx5 (GMT) can induce direct reprogramming of fibroblasts into induced cardiomyocytes (iCMs), in mice. However, in humans, additional factors, such as Mesp1 and Myocd, are required. Inflammation and immune responses hinder the reprogramming process in mice, and epigenetic modifiers such as TET1 are involved in direct cardiac reprogramming in humans. The three main approaches to improving reprogramming efficiency are (1) improving direct cardiac reprogramming factors, (2) improving cell culture conditions, and (3) regulating epigenetic factors. miR-133 is a potential candidate for the first approach. For the second approach, inhibitors of TGF-β and Wnt signals, Akt1 overexpression, Notch signaling pathway inhibitors, such as DAPT ((S)-tert-butyl 2-((S)-2-(2-(3,5-difluorophenyl) acetamido) propanamido)-2-phenylacetate), fibroblast growth factor (FGF)-2, FGF-10, and vascular endothelial growth factor (VEGF: FFV) can influence reprogramming. Reducing the expression of Bmi1, which regulates the mono-ubiquitination of histone H2A, alters histone modification, and subsequently the reprogramming efficiency, in the third approach. In addition, diclofenac, a non-steroidal anti-inflammatory drug, and high level of Mef2c overexpression could improve direct cardiac reprogramming.Direct cardiac reprogramming needs improvement if it is to be used in humans, and the molecular mechanisms involved remain largely elusive. Further advances in cardiac reprogramming research are needed to bring us closer to cardiac regenerative therapy.

Pluripotent Reprogramming and Lineage Reprogramming: Promises and Challenges in Cardiovascular Regeneration

In Vivo Lineage Reprogramming of Fibroblasts to Cardiomyocytes for Heart Regeneration

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair

Partial Cell Fate Transitions to Promote Cardiac Regeneration

Recent advances and future prospects in direct cardiac reprogramming

Improving Cardiac Reprogramming for Heart Regeneration in Translational Medicine

Non-viral approaches for somatic cell reprogramming into cardiomyocytes.

Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy

Another possible cell source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells.

Direct Reprogramming of Fibroblasts into Cardiomyocytes

Pluripotent stem cell-based heart regeneration: from the developmental and immunological perspectives.

Reprogramming Fibroblasts Toward Cardiomyocytes, Neural Stem Cells and Hepatocytes by Cell Activation and Signaling-Directed Lineage Conversion

Direct Reprogramming of Cardiac Fibroblasts to Repair the Injured Heart

Regulation of cardiomyocyte fate plasticity: a key strategy for cardiac regeneration

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy

Cardiac regeneration by direct reprogramming in this decade and beyond

Direct Cardiac Reprogramming in the Age of Computational Biology

Human Pluripotent Stem Cell-Derived Cardiovascular Progenitors for Heart Regeneration

Direct cardiac reprogramming: Toward the era of multi-omics analysis.

Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis

Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation